hero image

Biogen Files Form 8-K

May 3, 2023 Company Statements

Biogen today filed a Form 8-K with the United States Securities and Exchange Commission, disclosing that "On May 3, 2023, the European Commission notified Biogen Inc. of its decision that the period of regulatory market protection for Tecfidera extends until February 2, 2025.”

Biogen confirms that it has adequate capacity and supply of Tecfidera for patients in Europe through the period of its marketing protection and beyond.

thumb
June 1, 2023
Biogen Announces Webcast of Annual Meeting of Stockholders

Cambridge, Mass. – June 1, 2023 – Biogen Inc. (Nasdaq: BIIB) announced today that the webcast of the Company's 2023 Annual Meeting of Stockholders will be held on Wednesday, June 14, 2023, at 9:00 a.m. Eastern Time.  A live audio webcast of the meeting will be available on the Investor Relations

thumb
May 23, 2023
Biogen to Participate in the Jefferies Healthcare Conference

Cambridge, MA, - -  Biogen Inc.   (Nasdaq: BIIB) announced today that Michael McDonnell, Chief Financial Officer, and Priya Singhal, M.D., M.P.H., Head of Development, will participate in the Jefferies Healthcare Conference. The webcast will be live on Wednesday, June 7, 2023, at 11:30 a.m.